Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adoption to clinical practice. OBJECTIVE: To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service. METHODS: A Markov model simulated the progression of cardiovascular disease and MACE, including myocardial infarction, stroke, angina pectoris, and coronary revascularisation, in dyslipidaemia patients. The model was populated with cardiovascular outcome trial data for each drug. Cost and utility data were extracted from peer-reviewed literature. The incremental cost-effectiveness ratio (ICER) is reported per quality-adjusted life years (QALY) gained in 2021 Great Britain Pounds (£). RESULTS: For primary cardiovascular prevention, icosapent ethyl increased QALYs by 0.79 and costs by £15,421 compared to statin monotherapy (ICER = £19,485/QALY). Fenofibrate yielded 0.62 additional QALYs at cost-savings of - £6127 (ICER = - £9932/QALY). For secondary prevention, the omega-3 fatty acid icosapent ethyl extended QALYs by 0.98 at costs of £12,981 compared to statin monotherapy (ICER = £13,285/QALY). Fenofibrate added 0.85 QALYs whilst saving - £637 (ICER = - £7472/QALY). Ezetimibe increased QALYs by 0.60 at cost reductions of - £2529 (ICER = - £4231/QALY). PCSK9 inhibitors provided QALYs of 0.53 and 0.86 at costs of £45,279 and £46,375 for evolocumab (ICER = £85,193/QALY) and alirocumab (ICER = £54,211/QALY), respectively. At a willingness-to-pay threshold of £25,000/QALY, there is a probability of 100% for icosapent ethyl (98% in primary prevention) and 0% for PCSK9 inhibitors to be cost effective in secondary prevention. CONCLUSIONS: Icosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Markov model structure of cardiovascular diseases progression and acute events. Patients commence the model in the “Alive without CVD” (primary prevention) or “Alive with CVD” (secondary prevention) state. Every year patients were at risk of experiencing acute cardiovascular events (myocardial infarction, stroke, coronary revascularisation, unstable angina pectoris) and dying from CVD or non-CVD causes. Model structure adopted from Michaeli et al. [23]. CVD cardiovascular disease](https://figures.cochat.ai/paper-figures/5022069812684909b78dd306333cd312/cost-effectiveness-of-icosapent-ethyl-evolocumab-alirocumab-ezetimibe-or-figure-1.jpg)
![Fig. 2 Cost-effectiveness plane for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. QALYs and costs presented for the average person simulated in the model. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. Costs in 2021 Great Britain Pounds (£). QALY quality-adjusted life year](https://figures.cochat.ai/paper-figures/e3ea919286dd43fda3f8bf398cf3b985/cost-effectiveness-of-icosapent-ethyl-evolocumab-alirocumab-ezetimibe-or-figure-2.jpg)
![Fig. 3 Probabilistic sensitivity analysis for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. Input parameters displayed in Table 1 were varied by their confidence intervals and distribution; 1000 simulations of this probabilistic sensitivity analysis are visualised in this Figure. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Lipid-lowering drugs are presented as cholesterol- and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£). ICER incremental cost-effectiveness ratio, NHS National Health Service, QALY quality-adjusted life year](https://figures.cochat.ai/paper-figures/1bd0f93118e64906b47bcc7b2dda223f/cost-effectiveness-of-icosapent-ethyl-evolocumab-alirocumab-ezetimibe-or-figure-3.jpg)
![Fig. 4 Probability of cost effectiveness at different willingness-to-pay thresholds for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Dotted lines show the willingness-to-pay thresholds at which the probability of cost-effectiveness surpasses 95%. Lipid-lowering drugs are presented as cholesterol-and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£) and willingness-to-pay thresholds in £/QALY. NHS National Health Service, QALY quality-adjusted life year](https://figures.cochat.ai/paper-figures/3e58e517d3cd4410931e25d80b7e41c5/cost-effectiveness-of-icosapent-ethyl-evolocumab-alirocumab-ezetimibe-or-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, high prices for new treatments, such as PCSK9 inhibitors, have been identified as a barrier to swift coverage and reimbursement by insurers [21–24].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, recent economic analyses found icosapent ethyl could be a cost-effective treatment, particularly for secondary cardiovascular prevention, in the USA, Germany, UK, Canada, Australia, and Japan [22, 23, 116–121].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · cited 1×
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1×
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 1×
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 1×
“Both indicators function as independent markers to detect at-risk patients [12, 13].”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“Nicotinic acid in combination with laropiprant was excluded based on a negative EMA recommendation after the results of the HPS2-THRIVE study in 2013 [9].”
MethodPreiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · cited 1×
“in addition to safety concerns surrounding high statin doses [3, 4].”
BackgroundPleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247 · cited 1×
“Nonetheless, statins and icosapent ethyl exert beneficial pleiotropic effects on molecular pathways beyond lipid modification to achieve the MACE risk reduction observed in clinical trials [8, 14].”
BackgroundEuropean Society of Cardiology: Cardiovascular Disease Statistics 2019
Timmis, A., Townsend, N., Gale, C. P., Torbica, A., Lettino, M., Petersen, S. E., Mossialos, E. A., Maggioni, A. P., Kazakiewicz, D., May, H. T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz859 · Cited by 1,017 · cited 1×
“the National Health Service’s (NHS) annual healthcare budget is spent on CVD [15], which further increases pressure to introduce cost-effective prevention strategies.”
BackgroundBhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
British National Formulary: BNF
(2015) · doi:10.18578/bnf_147942626 · Cited by 641
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 205
Alva, M. L., Gray, A., Mihaylova, B., Leal, J., & Holman, R. R. (2015) · Diabetic Medicine · doi:10.1111/dme.12647 · Cited by 192 · cited 3×
“Costs for acute events amounted to £7842 for non-fatal MI, £11,512 for non-fatal stroke, £3517 for unstable angina, and £7337 for coronary revascularisation [27, 28].”
BackgroundKlempfner, R., Erez, A., Sagit, B.-Z., Goldenberg, I., Fisman, E., Kopel, E., Shlomo, N., Israel, A., & Tenenbaum, A. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002104 · Cited by 180 · cited 1×
“Both indicators function as independent markers to detect at-risk patients [12, 13].”
BackgroundLewis, E. F., Li, Y., Pfeffer, M. A., Solomon, S. D., Weinfurt, K. P., Velazquez, E. J., Califf, R. M., Rouleau, J. L., Køber, L., White, H. D., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.12.003 · Cited by 138
Watkinson, R., Sutton, M., & Turner, A. J. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30287-5 · Cited by 126
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
Fonarow, G. C., van Hout, B., Villa, G., Arellano, J., & Lindgren, P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1647 · Cited by 91
FISHing for the Miracle of Eicosapentaenoic Acid
Kastelein, J. J. P., & Stroes, E. S. G. (2019) · New England Journal of Medicine · doi:10.1056/nejme1814004 · Cited by 74
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Harrington, R. A., Higuchi, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.029 · Cited by 63
Michaeli, D. T., Mills, M. J., & Kanavos, P. G. (2022) · Applied Health Economics and Health Policy · doi:10.1007/s40258-022-00737-w · Cited by 47
Self-citationCost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
Azari, S., Rezapour, A., Omidi, N., Alipour, V., Behzadifar, M., Safari, H., Tajdini, M., & Bragazzi, N. L. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09874-2 · Cited by 44
Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J., & Ray, K. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013255 · Cited by 42
Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Azough, A., Khunti, K., Seshasai, S. R. K., & Ray, K. K. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011805 · Cited by 41 · cited 4×
“Costs for the “Alive without CVD” state of £2497 per year were based on healthcare expenditure in dyslipidaemia patients without history of any cardiovascular event [26].”
BackgroundInfluentialMichaeli, D. T., Mills, M. J., Michaeli, T., Miracolo, A., & Kanavos, P. G. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01227-5 · Cited by 38
Self-citationMarquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00936-0 · Cited by 34 · cited 1×
“Second, endpoints were converted to annual transition probabilities using the median follow-up of each CVOT (Supplementary Table e2), coherent with previous cost-effectiveness studies [16, 25].”
MethodReifsnider, O. S., Kansal, A. R., Franke, J., Lee, J. H., George, J. T., Brueckmann, M., Kaspers, S., Brand, S. B., Ustyugova, A., Linden, S., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12985 · Cited by 32 · cited 4×
“Costs for acute events amounted to £7842 for non-fatal MI, £11,512 for non-fatal stroke, £3517 for unstable angina, and £7337 for coronary revascularisation [27, 28].”
BackgroundInfluentialAdemi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487319896648 · Cited by 30
Are PCSK9 Inhibitors Cost Effective?
Korman, M. J., Retterstøl, K., Kristiansen, I. S., & Wisløff, T. F. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0671-0 · Cited by 28
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23 · cited 1×
“Similar to previous studies, baseline transition probabilities were multiplied by + 10% and + 14% annually to model the age-dependent increased risk of non-CVD and CVD events, respectively [23].”
Self-citationBagepally, B. S., & Sasidharan, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03242-6 · Cited by 22
Kodera, S., Morita, H., Kiyosue, A., Ando, J., & Komuro, I. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-0995 · Cited by 21
Sarajlic, P., Artiach, G., Larsson, S. C., & Bäck, M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07212-z · Cited by 19
Gao, L., Moodie, M., & Li, S.-C. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.001 · Cited by 17
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
Weintraub, W. S., Bhatt, D., Zhang, Z., Zhang, C., Sarahfaye, D., Boden, W. E., Steg, P. G., Miller, M., Brinton, E., King, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(20)32541-9 · Cited by 13
Lachaîne, J., Charron, J. N., Grégoire, J. C., Hegele, R. A., & Leiter, L. A. (2020) · Value in Health · doi:10.1016/j.jval.2020.08.546 · Cited by 8
Lachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s377935 · Cited by 7
Research works printed but not linked: 2
- 19. Ollendorf DA, McQueen RB, Campbell JD, Synnott PG, Herron- Smith S, Fazioli K, et al. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Eco- nomic Review; 2019. Available from: https:// icer. org/ asses sment/ cvd-addit ive-thera pies-2019/. Accessed 22 Mar 2022.
- 31. Joint Formulary Committee. British national formulary 80. Lon- don: BMJ Publishing and the Royal Pharmaceutical Society; 2020.
Cited by
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Self-citationPCSK9 inhibition: from effectiveness to cost-effectiveness
Mercep, I., Strikic, D., Hrabac, P., Pecin, I., & Reiner, Ž. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1339487 · Cited by 31
Soleimani, H., Mousavi, A., Shojaei, S., Tavakoli, K., Salabat, D., Rad, F. F., Askari, M. K., Nelson, J. R., Ruzieh, M., & Hosseini, K. (2024) · Clinical Cardiology · doi:10.1002/clc.24334 · Cited by 25
“Furthermore, ezetimibe combined with low/moderate ‐ intensity statin is available, affordable, and cost ‐ effective [50].”
BackgroundPresent and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
Morton, J. I., Liew, D., Watts, G. F., Zoungas, S., Nicholls, S. J., Dixon, P., & Ademi, Z. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf114 · Cited by 12
Metadata
- Authors
- Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T.
- Affiliations
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Michaeli, Daniel Tobias
- Venue
- Clinical Drug Investigation
- Published
- 2022-07-11
- Volume
- 42
- Issue
- 8
- Pages
- 643-656
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- PMC
- PMC9338124
- OpenAlex
- W4285077730
- Semantic Scholar
- 0212bfedf7028d5256bdd0c29411ddca573915f5
- Cited by
- 20
- References
- 44
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 7 · 2023: 3
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Drug Investigation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (acceptedVersion, cc-by-nc)
- Funders
- Medizinische Fakultät Mannheim der Universität Heidelberg
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- icosapent ethyl, evolocumab, alirocumab, ezetimibe, fenofibrate, statin combination therapy, statin monotherapy, cost-effectiveness, major adverse cardiovascular events, dyslipidemia, omega-3 fatty acids, PCSK9 inhibitors, primary prevention of cardiovascular disease, secondary prevention of cardiovascular disease, quality-adjusted life years, National Health Service
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, Cardiovascular Diseases, Cost-Benefit Analysis, Humans, Myocardial Infarction, Fenofibrate, State Medicine, Eicosapentaenoic Acid, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.